Simvastatin in Waldenstrom's Macroglobulinemia

Summary

This research study seeks to find new ways to treat people with Waldenstrom's Macroglobulinemia (WM). The study is for participants with slow growing WM who otherwise might not need therapy for at least 3-6 months. Simvastatin is a drug approved by the FDA for lowering cholesterol. In test tube studies the study drug appears to have direct anti-cancer effect against WM tumor cells and mast cells.

Timeline

Start

2007-11

Primary completion

2011-12

Completion

2011-12

Drugs

Indications